GLP-1 and Longevity

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells the brain you're full, slows how fast your stomach empties, and helps control insulin.

GLP-1 agonists are lab-made versions that copy that signal and stick around in the body much longer. The main drugs:

- Semaglutide, sold as Ozempic (diabetes) or Wegovy (obesity). Weekly injection. - Tirzepatide, sold as Mounjaro (diabetes) or Zepbound (obesity). Hits two hunger receptors (GLP-1 and GIP) instead of one. - Liraglutide, the older version. Daily injection.

These drugs were built for type 2 diabetes. But the weight loss in trials was so big (10 to 22 percent of body weight in phase-3 studies) that regulators also cleared them for obesity. The longevity question is separate: do they help people live longer or healthier, beyond just the weight loss?

This guide is not medical advice. GLP-1 agonists are prescription drugs with real risks. Talk to your doctor.

Here's the most important idea to get right: losing weight and living longer are not the same thing, even when they look related.

Long-running observational studies show obesity (BMI over 30) is linked to losing several years of life expectancy. So reversing obesity should in theory win some of those years back. But:

- Intentional weight loss through diet or surgery does lower death rates in people with obesity. The effect is real but smaller than most people think. Look-AHEAD and SOS found roughly 10 to 15 percent over 10-plus years. - In people with a normal BMI, there is no evidence yet that GLP-1 extends life. Every trial has been in people with obesity or diabetes. - Weight loss also burns off muscle, usually about 25 to 40 percent of the weight you lose. Lose muscle and you risk worse mobility and worse metabolic health later, unless you add strength training and enough protein.

So the real longevity question is: are there benefits beyond the weight loss itself? Early studies point to a few believable ways that could work. But the data are still young.

Three big randomised trials drive the current longevity debate:

SELECT (2023, NEJM): 17,604 people with obesity and existing heart disease, but no diabetes. They took semaglutide 2.4 mg weekly for 40 months. The result: a 20 percent drop in major heart-and-blood-vessel events (death, heart attack, stroke). This is the strongest evidence so far for a heart-protective, and possibly lifespan-related, effect.

STEP-HFpEF (2023): Semaglutide in people with heart failure (the kind where the heart pumps but stays stiff) and obesity. Symptoms and exercise capacity improved.

FLOW (2024): Semaglutide in people with type 2 diabetes and chronic kidney disease. A 24 percent drop in major kidney and heart-and-blood-vessel events.

What we still don't know: - Direct lifespan data over 10-plus years - The effect in people without risk factors (healthy-weight BMI) - Long-term safety across multiple decades - Whether the benefits stick around after you stop (early hint: most of the weight comes back within 1 to 2 years)

A 10-year follow-up arm of SELECT is running now. It should deliver solid death-rate data around 2033.

GLP-1 agonists are not harmless supplements. Common and serious risks include:

Common (10 to 40 percent of users): - Nausea, especially in the first weeks - Diarrhoea or constipation - Vomiting - Loss of appetite (that's the point, but it can tip into eating too little)

Less common but serious: - Pancreatitis (inflamed pancreas). Get medical help right away. - Gallbladder problems, including a higher risk of gallstones and cholecystitis. - Gastroparesis (stomach empties too slowly). This matters before surgery and anaesthesia. - Thyroid tumours in animal studies. The risk to humans is unclear. Not for people with MEN-2. - Muscle and bone loss if you don't plan around it.

Mental health: Reports of mood changes and, in a few cases, suicidal thoughts are still being reviewed by regulators. The EMA concluded in 2024 that no cause-and-effect link was proven, but monitoring continues.

Cost and supply: In most of Europe, these drugs are reimbursed for diabetes but self-pay for plain obesity (around 200 to 300 euros a month). Supply shortages have been common since 2023.

For the longevity community, the picture has nuance.

If you have obesity or type 2 diabetes: the data are now solid enough that GLP-1 agonists count among the most effective tools we have, with direct heart and kidney benefits. That decision belongs with a doctor, ideally one with endocrinology or cardiology expertise.

At a normal weight, optimising for longevity: this is speculation, not science. Off-label low-dose use gets talked about in longevity circles (especially in the US), but the evidence is basically not there. The known risks (muscle loss, gut side effects, rare serious problems) don't disappear just because the proven benefit isn't there yet.

Non-negotiable companions to any GLP-1 use: - Strength training (2 to 3 times a week) to keep muscle - Higher protein intake (1.6 to 2.0 g per kg body weight) - Regular DEXA or InBody scans to track body composition - Heart checkups and blood work per your doctor's plan

What the research actually says: a healthy body is the means, not the goal. Any tool that reverses obesity has plausible longevity potential. But thinness at any cost is not a health goal. GLP-1 with training is not the same outcome as GLP-1 without training.